Dolasetron
DefinitionThis section has been translated automatically.
5-HT3 antagonist, antiemetic.
Pharmacodynamics (Effect)This section has been translated automatically.
Selective, competitive binding to 5-HT3 receptors in the brain, among other places. As a result, serotonin can no longer bind to its binding sites at the 5-HT3 receptors and exert its effect. This directly prevents the development of nausea and vomiting, among other things.
IndicationThis section has been translated automatically.
Prophylaxis of cytostatic-induced nausea and vomiting.
Pregnancy/nursing periodThis section has been translated automatically.
Strictest indication for use during pregnancy. Use only if it can be assumed that the expected therapeutic benefit for the patient outweighs any risk to the fetus. Lactation: Do not use during lactation or weaning before therapy, as it is not known whether the active substance passes into breast milk (insufficient data available).
Dosage and method of useThis section has been translated automatically.
Undesirable effectsThis section has been translated automatically.
- Cutaneous ADRs: Occasional allergic or anaphylactic reactions. Slight exanthematic skin changes, flush and edema. Local reactions at the infusion site (burning, erythema, wheals).
- Extracutaneous ADRs: Headache (about 20-40% of patients), dizziness (10-15%), hypertension, lymphadenopathy, gastrointestinal disorders such as constipation or diarrhea (10-16%), arthralgia, fatigue (20-25%), flu-like symptoms with fever (3-5%) and chills.
ContraindicationThis section has been translated automatically.
Use in children, severe cardiac arrhythmias (especially in comedication with antiarrhythmics), hypersensitivity reactions to other 5-HT3 antagonists.
PreparationsThis section has been translated automatically.
Anemet